phosphatidylinositol transfer protein membrane associated 1Genealiases: DRES9 · NIR2 · PITPNM · RDGB · RDGB1 · RDGBA
Q-omics provides the consensus-scored PITPNM1 profile across patient tissues and cancer cell-line models. PITPNM1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PITPNM1 is differentially expressed in 12, with the highest sampling consensus in STAD. Additionally, PITPNM1 protein abundance shows 18,785 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, STAD, and LSCC as cancer lineages where PITPNM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PITPNM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PITPNM1 survival associations across molecular data types. PITPNM1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PITPNM1 RNA expression–survival associations across cancer types. High PITPNM1 expression shows unfavorable associations in ACC, LUSC, DLBC and OV, but favorable associations in STAD and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PITPNM1 RNA expression.
This table summarizes PITPNM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PITPNM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PITPNM1 shows lower tumor expression in KICH and KIRC and higher tumor expression in STAD, LIHC, LUAD and HNSC. The STAD box plot shows higher PITPNM1 RNA expression in tumor versus normal tissue (log2 FC = +1.666, t-test p < 0.001).
This table shows molecular features associated with PITPNM1 in patient tissues and cancer cell lines. In patient samples, PITPNM1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PITPNM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
